selected publications
- Autologous stem cell transplantation for the treatment of MGRS (monoclonal gammopathy of renal significance): experience from the University of Calgary. Leukemia & lymphoma. 2025 Academic Article GET IT
- Artificial intelligence-driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2025 Academic Article GET IT
- Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myeloma. Future oncology (London, England). 2025 Academic Article GET IT
- Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database. Clinical lymphoma, myeloma & leukemia. 2025 Academic Article GET IT
- Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database. Clinical lymphoma, myeloma & leukemia. 2025 Academic Article GET IT
- Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study. Blood cancer journal. 2025 Letter GET IT
- Case report of isolated aortic valve AL-amyloidosis following aortic valve replacement. 2025 GET IT
- BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis. Current oncology (Toronto, Ont.). 2025 Review GET IT
- Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, Canada. Clinical lymphoma, myeloma & leukemia. 2025 Academic Article GET IT
- Longitudinal Changes in Multiple Cardiac Biomarkers in Transthyretin Amyloidosis Cardiomyopathy Patients Treated Vs Untreated with Tafamidis. CJC open. 2025 Academic Article GET IT
- Role of a Multidisciplinary Program (Amyloidosis Program of Calgary) on Recognition and Intervention for AL and ATTR Amyloidosis. Clinical lymphoma, myeloma & leukemia. 2025 Academic Article GET IT
-
Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 Years.
Canadian journal of kidney health and disease.
2025
Academic Article
GET IT
Times cited: 1 -
Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review.
Current oncology (Toronto, Ont.).
2024
Academic Article
GET IT
Times cited: 1 - Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary. Current oncology (Toronto, Ont.). 2024 Academic Article GET IT
- Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database. EJHaem. 2024 Academic Article GET IT
- Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC). Leukemia & lymphoma. 2023 Academic Article GET IT
-
Long-term survivorship care after CAR-T cell therapy.
European journal of haematology.
2023
Review
GET IT
Times cited: 20 -
Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary.
Clinical lymphoma, myeloma & leukemia.
2023
Letter
GET IT
Times cited: 3 -
Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria.
Clinical lymphoma, myeloma & leukemia.
2022
Academic Article
GET IT
Times cited: 6 - Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data. Leukemia & lymphoma. 2022 Letter GET IT
-
Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone.
Clinical lymphoma, myeloma & leukemia.
2022
Academic Article
GET IT
Times cited: 2 -
Amyloidosis and COVID-19: experience from an amyloid program in Canada.
Annals of hematology.
2022
Academic Article
GET IT
Times cited: 16 -
Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada.
Leukemia & lymphoma.
2022
Academic Article
GET IT
Times cited: 3 -
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
British journal of haematology.
2022
Academic Article
GET IT
Times cited: 8 -
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
Current oncology (Toronto, Ont.).
2022
Academic Article
GET IT
Times cited: 3 -
N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution.
Annals of hematology.
2021
Academic Article
GET IT
Times cited: 8 -
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
European journal of haematology.
2021
Academic Article
GET IT
Times cited: 5 -
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Haematologica.
2021
Letter
GET IT
Times cited: 10 -
Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion.
2021
Academic Article
GET IT
Times cited: 1 -
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
European journal of haematology.
2021
Academic Article
GET IT
Times cited: 1 -
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
British journal of haematology.
2021
Academic Article
GET IT
Times cited: 11 -
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
European journal of haematology.
2020
Academic Article
GET IT
Times cited: 3 -
The Prognostic Role of Lactate Dehydrogenase at First Relapse of Multiple Myeloma.
Acta haematologica.
2020
Comment
GET IT
Times cited: 10 -
Anti-myeloma potential of ruxolitinib in co-existing JAK2V617F-positive smouldering myeloma and polycythaemia vera.
British journal of haematology.
2020
Letter
GET IT
Times cited: 3 -
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
Clinical lymphoma, myeloma & leukemia.
2019
Academic Article
GET IT
Times cited: 11 -
Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.
Clinical lymphoma, myeloma & leukemia.
2017
Academic Article
GET IT
Times cited: 10 -
Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
Annals of hematology.
2017
Academic Article
GET IT
Times cited: 23 -
Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Clinical lymphoma, myeloma & leukemia.
2016
Academic Article
GET IT
Times cited: 14 -
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.
Cancer research.
2009
Academic Article
GET IT
Times cited: 142